Agilent Technologies announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow. This allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours, a process that often takes two days or more with traditional FISH.

The new panel, comprising of ALK, ROS1, RET and MET IQFISH probes, was designed using the groundbreaking, oligonucleotide-based SureFISH technology utilizing formamide-free IQFISH fast hybridization buffer.

Also read: Australia changes drug approval norms to speed up approval process

"We are excited about the upcoming probe launches for Dako Omnis," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome."

The lung cancer panel is the second IQFISH launch for Dako Omnis following its introduction of HER2 IQFISH pharmDx in 2015.